We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Enzyme Adapted to Enhance Nerve Agent Detoxification Capacity

By LabMedica International staff writers
Posted on 23 May 2012
Researchers have used directed evolution of a human liver enzyme to enhance its capacity to detoxify the most threatening known G-type nerve agents. More...
The improved versions are promising candidates for preventative preexposure treatment as well as for postexposure detoxification.

Today, protection against toxic nerve agents relies primarily on physical barriers such as gas masks and protective suits that can easily be breached, explained Dr. Moshe Goldsmith of the Weizmann Institute of Science (Rehovot, Israel). Following exposure, people are treated with drugs that help with the symptoms but do not eliminate the nerve agent.

Dr. Goldsmith and Prof. Dan Tawfik, senior author of the study, hope to change this, relying on the principles of molecular evolution to produce a more efficient version of an enzyme that occurs naturally in the liver. Known as paraoxonase 1 (PON1), this enzyme was originally named for its ability to assist in the breakdown of the insecticide paraoxon. It is also involved in drug metabolism and detoxification.

PON1 normally does counteract G-type nerve agents, including sarin, tabun, soman, and cyclosarin, but not well enough. Prof. Tawfik's lab, at Weizmann Institute’s Department of Biological Chemistry, specializes in the technique of "directed enzyme evolution”, in which mutations are artificially introduced into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria to produce the enzymes used for testing.

The goal was to end up with enzymes capable of detoxifying G-type nerve agents before they could reach their target and cause harm. Enzymes that passed the initial test went on to further rounds of evolution and testing. After four rounds of evolution, PON1 variants were obtained that worked up to 340 times better than those produced previously did. Overall, the researchers reported that the adapted PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

“Both the raw materials and know-how of producing deadly nerve agents are available to people outside government or military institutions," said Dr. Goldsmith; "We hope that our work would provide a prophylactic drug that will effectively protect the medical, police, and other teams that will have to act in a contaminated area following such an attack, and would also provide these teams with a drug that could be administered on-site to intoxicated individuals to greatly improve their chances of survival."

More broadly, the findings, published April 20, 2012, in the Cell Press journal Chemistry and Biology, further show the power of laboratory evolution to reshape existing enzymes for a variety of uses.

Related Links:

Weizmann Institute of Science



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.